Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study comparing pharmacokinetics, safety, and tolerability of FYB202 with reference drug Stelara

Next Previous
X
Search
Trial Profile

A clinical study comparing pharmacokinetics, safety, and tolerability of FYB202 with reference drug Stelara

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Immunological disorders
  • Focus Adverse reactions
  • Sponsors Bioeq

    • Most Recent Events

    • 20 Feb 2025 According to a Formycon media release, data from this study will be presented at the European Crohns and Colitis Organisation (ECCO) Congress
    • 17 Sep 2024 According to a Formycon media release, the company will present study data focusing on the pharmacokinetics of the ustekinumab biosimilar candidate FYB202 at the United European Gastroenterology (UEG) Week from October 12 to 15, 2024 in Vienna.
    • 25 Apr 2023 Results presented in the Formycon Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top